文献速递泌尿男性生殖肿瘤

年轻前列腺癌患者的主动监测

Active Surveillance in Younger Men With Prostate Cancer.
PubMed 文献 · J Clin Oncol · 2017-03-27

本研究在本机构接受主动监测(AS)且随访至少6个月的前列腺癌(PCa)患者中,分析年龄与活检Gleason评分升级风险的关系。共纳入1433例患者,中位随访49个月,年龄≤60岁者3年和5年活检Gleason评分无升级率分别为73%和55%,高于>60岁者的64%和48%(P<.01);年轻年龄与活检Gleason评分升级风险降低独立相关,但与接受确定性治疗或延迟根治性前列腺切除术后生化复发风险无显著关联。

要点

  • 年轻年龄与AS期间活检Gleason评分升级风险降低独立相关(每年轻1岁HR 0.969)。
  • ≤60岁者3年和5年活检Gleason评分无升级率为73%和55%,>60岁者为64%和48%(P<.01)。
  • 年轻年龄与确定性治疗风险及延迟根治性前列腺切除术后生化复发风险无显著关联。

核心结论

  • 年轻患者年龄与AS期间活检Gleason评分升级风险降低相关,但在中期随访中与确定性治疗风险无关。
  • AS是早期低危年轻前列腺癌患者减少过度治疗的一种策略。

研究设计与样本

  • 本研究为在本机构接受主动监测(AS)且随访至少6个月的前列腺癌患者队列,共纳入1433例,中位随访49个月。
  • 主要研究目标是分析年龄与AS期间活检Gleason评分升级风险的关系。
  • 同时分析年龄与活检确定的总体进展、确定性治疗以及延迟根治性前列腺切除术后病理和生化结局的关系,采用描述性统计、Kaplan-Meier法和多因素Cox比例风险回归。
  • 诊断时中位年龄63岁,其中≤60岁599例(42%),>60岁834例(58%);74%的患者初始活检在转诊机构完成。

主要发现

  • ≤60岁男性3年和5年活检Gleason评分无升级率分别为73%和55%,>60岁男性分别为64%和48%(P<.01)。
  • Cox回归分析中,年轻年龄与活检Gleason评分升级风险降低独立相关(每年轻1岁,风险比0.969 [95%CI,0.956至0.983];P<.01),在限定符合严格AS入选标准的男性后该关联仍存在。
  • 年轻年龄与确定性治疗风险或延迟根治性前列腺切除术后生化复发风险之间无显著关联。

关键数值与推荐

  • 活检Gleason评分无升级率:≤60岁男性3年73%、5年55%;>60岁男性3年64%、5年48%(P<.01)。
  • 活检Gleason评分升级风险:每年轻1岁,风险比0.969(95%CI,0.956至0.983;P<.01)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose The suitability of younger patients with prostate cancer (PCa) for initial active surveillance (AS) has been questioned on the basis of eventual treatment necessity and concerns of safety; however, the role of age on surveillance outcomes has not been well defined. Patients and Methods We identified men managed with AS at our institution with a minimum follow-up of 6 months. The primary study objective was to examine the association of age with risk of biopsy-based Gleason score upgrade during AS. We also examined the association of age with related end points, including overall biopsy-determined progression, definitive treatment, and pathologic and biochemical outcomes after delayed radical prostatectomy (RP), using descriptive statistics, the Kaplan-Meier method, and multivariable Cox proportional hazards regression. Results A total of 1,433 patients were followed for a median of 49 months; 74% underwent initial biopsy at a referring institution. Median age at diagnosis was 63 years, including 599 patients (42%) ≤ 60 years old and 834 (58%) > 60 years old. The 3- and 5-year biopsy-based Gleason score upgrade-free rates were 73% and 55%, respectively, for men ≤ 60 years old compared with 64% and 48%, respectively, for men older than 60 years ( P < .01). On Cox regression analysis, younger age was independently associated with lower risk of biopsy-based Gleason score upgrade (hazard ratio per 1-year decrease, 0.969 [95% CI, 0.956 to 0.983]; P < .01), and persisted upon restriction to men meeting strict AS inclusion criteria. There was no significant association between younger age and risk of definitive treatment or risk of biochemical recurrence after delayed RP. Conclusion Younger patient age was associated with decreased risk of biopsy-based Gleason score upgrade during AS but not with risk of definitive treatment in the intermediate term. AS represents a strategy to mitigate overtreatment in young patients with low-risk PCa in the early term.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Leapman MS, Cowan JE, Nguyen HG, et al. Active Surveillance in Younger Men With Prostate Cancer. J Clin Oncol. 2017. PMID: 28346806. doi:10.1200/JCO.2016.68.0058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。